Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Diagnosis, treatment, and prognosis of bronchopulmonary carcinoid: an analysis of 74 patients

Chi, Yihebalia,*; Gao, Shugenga; Du, Fenga; Wang, Jin-wana; Jiang, Wen-changb; Sun, Yong-kuna; Song, Yana; He, Jiea

doi: 10.1097/CAD.0000000000000292
CLINICAL REPORTS
Buy

To investigate the initial symptoms, treatment, prognosis, and 1-, 3-, and 5-year survival of patients with bronchopulmonary carcinoid, clinical and pathological data were collected retrospectively from 74 patients diagnosed with bronchopulmonary neuroendocrine tumors at the Cancer Hospital, Chinese Academy of Medical Science, from January 2004 through December 2009. The data collected included age, initial symptoms, primary tumor sites, pathological types, lymphatic metastasis, and distant metastasis. The Kaplan–Meier method was used for survival analysis and the log-rank test was used for univariate analysis of prognostic factors. A Cox proportional hazard regression model was used for multivariate analysis. The 74 patients included 56 men and 19 women, and their average age was 56.07 years. The most common initial symptom was cough (51.35%), and the major lesion site was the left upper lobe of the lung (38.84%). Of the 59 patients (79.73%) who underwent surgery, most (76.27%) received a pulmonary lobectomy. The patients’ 1-, 3-, and 5-year survival rates were 92.7, 80.3, and 71.9%, respectively. Univariate analysis showed that both local lymphatic and distant metastases were prognostic factors (P<0.05), whereas multivariate analysis showed that the pathological type (typical carcinoid and atypical carcinoid) was an independent prognostic factor (P=0.006). These data indicate that cough is the major presenting symptom of patients with bronchopulmonary carcinoid and the left upper lobe of the lung is the most commonly involved site. Following treatment, mostly by pulmonary lobectomy, the 5-year survival rate is 71.9%. The pathological tumor type is an independent prognostic factor.

aDepartment of Medicine, Cancer Hospital, Chinese Academy of Medical Science

bDepartment of Oncology, People’s Hospital, Qinzhou, Shandong, China

* Yihebali Chi and Shugeng Gao contributed equally to the writing of this article.

Correspondence to Jie He, Department of Medicine, Cancer Hospital, Chinese Academy of Medical Science, Beijing, 100021, China Tel: +86 139 110 75626; fax: +86 010 88859155; e-mail: yihebalichi@hotmail.com

Received June 14, 2015

Accepted August 10, 2015

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.